Life Spine® Announces FDA Clearance of LONG BOW™ Expandable Lateral Interbody System
HOFFMAN ESTATES, Ill.–(BUSINESS WIRE)–Life Spine, a medical device company that designs, develops, manufactures and markets products for the surgical treatment of spinal disorders, announced today that the U.S. Food and Drug Administration (FDA) has given 510(k) marketing clearance to the LONG BOW Expandable Lateral Interbody System.
The innovative LONG BOW Expandable Lateral Interbody System is the first interbody on the market that expands laterally in-situ specifically for a direct lateral approach.
“With the LONG BOW interbody system, surgeons can decrease the amount of retraction by as much as 45% compared to current lateral systems. The benefits of LONG BOW are transferred directly to the patient by minimizing tissue retraction and potential nerve damage associated with the lateral access approach,” said Richard Greiber, Vice President of Business Development and Professional Relations.
LONG BOW is scheduled for limited release at the end of 2014 with full product release expected in the first quarter of 2015.
About Life Spine
Life Spine is dedicated to improving the quality of life for spinal patients by increasing procedural efficiency and efficacy through innovative design, uncompromising quality standards, and the most technologically advanced manufacturing platforms. Life Spine, which is privately held, is based in Hoffman Estates, Illinois. For more information, please visit http://www.lifespine.com.
Contacts
Life Spine
Mr. Omar Faruqi, 847-884-6117
Chief Financial Officer
ofaruqi@lifespine.com